{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:13:22Z","timestamp":1790820802013,"version":"4.1.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,11]]},"abstract":"<jats:p>Pyrrolizidine alkaloids induced hepatic sinusoidal obstruction syndrome (PA-HSOS) often occurs after consuming herbs or a dietary supplement containing the plant Tu-San-Qi. Limited data exists to identify patients with fatal outcomes for early interventions. We aimed to analyze the predictors for 3-month survival. We retrospectively enrolled PA-HSOS patients in 5 hospitals and extracted data from the onset of PA-HSOS to 36 months. Outcome measurements were 3-month and 36-month survival rates, baseline prognostic predictors for survival, and the effects of anticoagulant therapy. Among 49 enrollees, the median age was 60 and 49% male. At the onset of PA-HSOS, patients with Child-Turcotte-Pugh (CTP) class of A, B, or C were 8.2% (4\/49), 42.8% (21\/49) and 49.0% (24\/49), respectively. None of them received a transjugular intrahepatic portosystemic shunt or a liver transplant. The 3-month and 36-month survival rates were 86% and 76%, respectively. Compared to the CTP class A or B, class C at baseline independently predicted lower survival rates at both 3 and 36 months. However, anticoagulation therapy treatment within the first 3 months independently predicted significantly higher survival rates at both time points. CTP class C and anticoagulant therapy were the independent predictors for short-term and long-term survival. Anticoagulant therapy could decrease mortality rate of CTP class C patients.<\/jats:p>\n          <jats:p>The greatest benefit of anticoagulant evaluated by 3-month survival rate was in patients with CTP class C compared with those without treatment (93% vs 40%, <jats:italic toggle=\"yes\">P<\/jats:italic> = .009). There were no bleeding complications reported in patients treated with the anticoagulant.<\/jats:p>","DOI":"10.1097\/md.0000000000034698","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T14:01:57Z","timestamp":1691762517000},"page":"e34698","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic risk factors for patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids"],"prefix":"10.1097","volume":"102","author":[{"given":"Xiaofei","family":"Du","sequence":"first","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenli","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Yu","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Tongren Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengsheng","family":"Zou","sequence":"additional","affiliation":[{"name":"The Fifth Medical Center of PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongshan","family":"Wei","sequence":"additional","affiliation":[{"name":"Beijing Ditan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liang","sequence":"additional","affiliation":[{"name":"Tianjin Third Central Hospital, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daokun","family":"Yang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Xinxiang Medical University, Henan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3082-8330","authenticated-orcid":false,"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Youan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin Q.","family":"Pan","sequence":"additional","affiliation":[{"name":"Division on Gastroenterology and Hepatology, NYU Langone Health, NYU Grossman School of Medicine, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jhep.2015.07.040","article-title":"EASL clinical practice guidelines: vascular diseases of the liver.","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/bmt.2015.52","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives-a position statement from the European society for blood and marrow transplantation (EBMT).","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cld.2010.07.009","article-title":"Sinusoidal obstruction syndrome.","volume":"14","author":"Rubbia-Brandt","year":"2010","journal-title":"Clin Liver Dis"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury.","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.3748\/wjg.v25.i28.3753","article-title":"Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes.","volume":"25","author":"Yang","year":"2019","journal-title":"World J Gastroenterol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/jgh.14612","article-title":"Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.","volume":"34","author":"Zhuge","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12876-018-0879-7","article-title":"Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study.","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Gastroenterol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/MEG.0000000000001630","article-title":"Clinical efficacy and safety of anticoagulation therapy for Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective multicenter cohort study.","volume":"32","author":"Peng","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/liv.13684","article-title":"Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease.","volume":"38","author":"Zhuge","year":"2018","journal-title":"Liver Int"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2016.130","article-title":"Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European society for blood and marrow transplantation.","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"e28677","DOI":"10.1002\/pbc.28677","article-title":"Defibrotide treatment but not prophylaxis is useful in hepatic sinusoidal obstruction syndrome in children undergoing autologous stem cell transplant following high-dose chemotherapy: a single-center experience from the Royal Marsden Hospital, UK.","volume":"67","author":"Roy Moulik","year":"2020","journal-title":"Pediatric Blood Cancer"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1200\/JCO.1993.11.9.1729","article-title":"Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation.","volume":"11","author":"Bearman","year":"1993","journal-title":"J Clin Oncol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/ijms17010014","article-title":"RUCAM in drug and herb induced liver injury: the update.","volume":"17","author":"Danan","year":"2015","journal-title":"Int J Mol Sci"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3348\/kjr.2014.15.2.218","article-title":"Hepatic sinusoidal obstruction syndrome caused by herbal medicine: CT and MRI features.","volume":"15","author":"Zhou","year":"2014","journal-title":"Korean J Radiol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"37998","DOI":"10.1038\/srep37998","article-title":"Diagnostic performance of Contrast-enhanced CT in pyrrolizidine alkaloids-induced hepatic sinusoidal obstructive syndrome.","volume":"6","author":"Kan","year":"2016","journal-title":"Sci Rep"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1038\/s41598-019-38669-6","article-title":"Quantitative analysis of CT images in patients with pyrrolizidine alkaloid-induced sinusoidal obstruction syndrome.","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1053\/j.gastro.2019.02.002","article-title":"Incidence and etiology of drug-induced liver injury in mainland China.","volume":"156","author":"Shen","year":"2019","journal-title":"Gastroenterology"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41401-020-00553-9","article-title":"Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China.","volume":"42","author":"Zhu","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s12072-021-10293-5","article-title":"Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.","volume":"16","author":"Wang","year":"2022","journal-title":"Hepatol Int"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034698","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:23:27Z","timestamp":1746325407000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":19,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034698","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,11]]}}}